Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000904454-25-000502·JOHNSON & JOHNSON
Schedule 13G ownership disclosure
Rapport Therapeutics Inc
Common Stock, $0.001 par value · CUSIP: 75383L102
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- JOHNSON & JOHNSON
Shares: 1,784,517.00 · Class: 4.9%
- Johnson & Johnson Innovation - JJDC, Inc.
Shares: 1,784,517.00 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000904454-25-000502
- Form type
- SCHEDULE 13G/A
- Filer
- JOHNSON & JOHNSON
- CIK
- CIK 200406
- Filed
- Oct 22, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership